File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas

TitleA phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas
Authors
Issue Date2013
Citation
Oncologist, 2013, v. 18 n. 3, p. 271-272 How to Cite?
AbstractBackground. Esophageal and gastric cancers often present at an advanced stage. Systemic chemotherapy is the mainstay of treatment, but survival with current regimens remains poor. We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Methods. Thirty-seven patients with metastatic or unresectable gastric/gastroesophageal junction tumors were enrolled and treated with capecitabine 850 mg/m2 BID on days 1-14, and oxaliplatin 130 mg/m2 with bevacizumab 15 mg/kg on day 1 of a 21day cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints included response rate (RR) and overall survival (OS). Neuropilin-1 (NRP1) and -2 (NRP2) mRNA expression was evaluated in archived tumor. Results. Thirty-five patients were evaluable for efficacy. Median PFS was 7.2 months; median OS was 10.8 months. RR was estimated at 51.4%. The regimen was tolerable with expected drug class-related toxicities. NRP2 mRNA levels significantly correlated with PFS (p 0.042) and showed a trend toward significance with OS (p 0.051). Nonsignificant trends for NRP1 were noted for higher expression levels and worse outcome. Conclusions. Bevacizumab can be given safely with chemotherapy in patients with metastatic esophagogastric adenocarcinomas. The combination of capecitabine, oxaliplatin, plus bevacizumab has activity comparable to other bevacizumab-containing regimens in metastatic gastroesophageal cancer. © AlphaMed Press 2013.
Persistent Identifierhttp://hdl.handle.net/10722/194381
ISSN
2015 Impact Factor: 4.789
2015 SCImago Journal Rankings: 2.391
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorUronis, HE-
dc.contributor.authorBendell, JC-
dc.contributor.authorAltomare, I-
dc.contributor.authorBlobe, GC-
dc.contributor.authorDavid Hsu, S-
dc.contributor.authorMorse, MA-
dc.contributor.authorPang, H-
dc.contributor.authorYousuf Zafar, S-
dc.contributor.authorConkling, P-
dc.contributor.authorFavaro, J-
dc.contributor.authorArrowood, CC-
dc.contributor.authorCushman, SM-
dc.contributor.authorMeadows, KL-
dc.contributor.authorBrady, JC-
dc.contributor.authorNixon, AB-
dc.contributor.authorHurwitz, HI-
dc.date.accessioned2014-01-30T03:32:31Z-
dc.date.available2014-01-30T03:32:31Z-
dc.date.issued2013-
dc.identifier.citationOncologist, 2013, v. 18 n. 3, p. 271-272-
dc.identifier.issn1083-7159-
dc.identifier.urihttp://hdl.handle.net/10722/194381-
dc.description.abstractBackground. Esophageal and gastric cancers often present at an advanced stage. Systemic chemotherapy is the mainstay of treatment, but survival with current regimens remains poor. We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Methods. Thirty-seven patients with metastatic or unresectable gastric/gastroesophageal junction tumors were enrolled and treated with capecitabine 850 mg/m2 BID on days 1-14, and oxaliplatin 130 mg/m2 with bevacizumab 15 mg/kg on day 1 of a 21day cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints included response rate (RR) and overall survival (OS). Neuropilin-1 (NRP1) and -2 (NRP2) mRNA expression was evaluated in archived tumor. Results. Thirty-five patients were evaluable for efficacy. Median PFS was 7.2 months; median OS was 10.8 months. RR was estimated at 51.4%. The regimen was tolerable with expected drug class-related toxicities. NRP2 mRNA levels significantly correlated with PFS (p 0.042) and showed a trend toward significance with OS (p 0.051). Nonsignificant trends for NRP1 were noted for higher expression levels and worse outcome. Conclusions. Bevacizumab can be given safely with chemotherapy in patients with metastatic esophagogastric adenocarcinomas. The combination of capecitabine, oxaliplatin, plus bevacizumab has activity comparable to other bevacizumab-containing regimens in metastatic gastroesophageal cancer. © AlphaMed Press 2013.-
dc.languageeng-
dc.relation.ispartofOncologist-
dc.titleA phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1634/theoncologist.2012-0404-
dc.identifier.pmid23485624-
dc.identifier.scopuseid_2-s2.0-84875412388-
dc.identifier.volume18-
dc.identifier.issue3-
dc.identifier.spage271-
dc.identifier.epage272-
dc.identifier.isiWOS:000316783300007-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats